Compare ADMA Biologics Inc (ADMA) vs Carvana Co (CVNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Carvana Co — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Carvana Co trades at $65.81 (market cap $48.34B). The key difference: Carvana Co is far larger — about 22.7× ADMA Biologics Inc's market cap, and Carvana Co is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CVNA | |
|---|---|---|
Market Cap | $2.13B | $48.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $95.69 |
52-Week Low | $7.60 | $56.27 |
Enterprise Value | $2.20B | $50.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Carvana (CVNA) trades at $67.47, down 1.63% on the day, with a bullish technical signal and strong fundamental growth. Revenue surged to $20.32B in 2025, with net income reaching $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and expansion news includes same-day delivery in Milwaukee.
The outlook is positive with analyst consensus at Buy and a $93.92 price target, but risks include high debt levels and competitive pressures. Upside potential exists from operational efficiency and market expansion, yet volatility from used-car market softness remains a concern for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
